Citations

Clear

1315 citation(s) found for "Kyle, RA".

Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes
Jackson, Kyle R. , Bowring, Mary G. , Chen, Jennifer , Waldram, Madeleine M. , Benedetti, Enrico , Ratner, Lloyd E. , Kapur, Sandip , Pelletier, Ronald P. , Melcher, Marc L. , Singh, Pooja , Sudan, Debra L. , Posner, Marc P., El‐Amm, Jose M., Shapiro, Ron , Cooper, Matthew , Verbesey, Jennifer , Lipkowitz, George S. , Rees, Michael A. , Sankari, Bashir R., Gerber, David A. , Wellen, Jason R., Bozorgzadeh, Adel , Heher, Eliot , Weng, Francis L. , Helderman, J. Harold, Brayman, Kenneth L. , Oberholzer, José , Kozłowski, Tomasz , Covarrubias, Karina , Desai, Niraj M. , Massie, Allan B. , Segev, Dorry L. , Garonzik‐Wang, Jacqueline , Cooper, Matthew , Melcher, Marc L , Segev, Dorry L , Sudan, Debra L , Gerber, David A , Long, Jane J. , Motter, Jennifer D. , Orandi, Babak John , Montgomery, Robert A. , Stegall, Mark D. , Jordan, Stanley C. , Dunn, Ty B , Roberts, John P. , Marsh, Christopher L. , Gaber, A. Osama , Djamali, Arjang , Concepcion, Beatrice P.

Mayo Clinic

Transplantation | April 1, 2020 | Volume: 105 | Issue: 2 | Pages: 436-442

10.1097/tp.0000000000003254 | PMID 32235255 Get It

Background. Desensitization protocols for HLA-incompatible living donor kidney transplantation (ILDKT) vary across centers. The impact of these, as well as other practice variations, on ILDKT outcomes remains unknown. Methods. We sought to quantify center-level variation in mortality and graft loss following ILDKT using a 25-center cohort of 1358 ILDKT recipients with linkage to Scientific Registry of Transplant Recipients for accurate outcome ascertainment. We used multilevel Cox regression with shared frailty to determine the variation in post-ILDKT outcomes attributable to between-center differences and to identify any center-level characteristics associated with improved post-ILDKT outcomes. Results. After adjusting for patient-level characteristics, only 6 centers (24%) had lower mortality and 1 (4%) had higher mortality than average. Similarly, only 5 centers (20%) had higher graft loss and 2 had lower graft loss than average. Only 4.7% of the differences in mortality (P < 0.01) and 4.4% of the differences in graft loss (P < 0.01) were attributable to between-center variation. These translated to a median hazard ratio of 1.36 for mortality and 1.34 of graft loss for similar candidates at different centers. Post-ILDKT outcomes were not associated with the following center-level characteristics: ILDKT volume and transplanting a higher proportion of highly sensitized, prior transplant, preemptive, or minority candidates. Conclusions. Unlike most aspects of transplantation in which center-level variation and volume impact outcomes, we did not find substantial evidence for this in ILDKT. Our findings support the continued practice of ILDKT across these diverse centers.
Evaluation of Saline, Phosphate-Buffered Saline, and Minimum Essential Medium as Potential Alternatives to Viral Transport Media for SARS-CoV-2 Testing
Rodino, Kyle G. , Espy, Mark J., Buckwalter, Seanne P., Walchak, Robert C., Germer, Jeffery J., Fernholz, Emily C. , Boerger, Aimee C. , Yao, Joseph D. , Binnicker, Matthew J. , Fernholz, Emily, Boerger, Aimee, Rodino, Kyle G , Schuetz, Audrey N.

Mayo Clinic

Journal of Clinical Microbiology | March 31, 2020 | Volume: 58 | Issue: 6 | Pages: No page available

10.1128/jcm.00590-20 | PMID 32229604 Get It

Dual RVAD-ECMO Circuits to Treat Cardiogenic Shock and Hypoxemia Due to Necrotizing Lung Infection: A Case Report
Rosenbaum, Andrew , Bohman, J. Kyle , Rehfeldt, Kent H., Stulak, John M., Daly, Richard C. , Klompas, Allan M. , Behfar, Atta , Yalamuri, Suraj , Behfar, Atta , Bohman, John K

Mayo Clinic

A&A Practice | March 24, 2020 | Volume: 14 | Issue: 6 | Pages: e01181

10.1213/xaa.0000000000001181 | PMID 32224696 Get It

Utilization of venoarterial extracorporeal membrane oxygenation (VA-ECMO) is expanding, but dual VA-ECMO circuits to treat cardiogenic shock with refractory hypoxemia is unreported. We describe the case of combined cardiogenic and distributive shock due to necrotizing pulmonary blastomycosis. After initial central VA-ECMO cannulation, acute respiratory distress syndrome (ARDS) with increasing shunt resulted in significant central hypoxemia due to progressive ventilation-perfusion mismatch. An additional circuit provided complete oxygenation of the high circulating volume. After 4 months on support, he underwent successful heart-lung-kidney transplantation. Dual ECMO circuits are technically feasible and may be advantageous in specific circumstances of high pulmonary shunting resulting in excessive hypoxemia unbalanced with appropriate oxygen delivery.
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition
Conley, Robert B., Adib, Gemma, Adler, Robert A. , Alexander, Ivy M. , Amenta, Kelly C, Blank, Robert D. , Brox, W. Timothy , Carmody, Emily E., Chapman‐Novakofski, Karen , Cody, Kathleen, Crandall, Carolyn , Dirschl, Douglas R. , Eagen, Thomas J. , Elderkin, Ann L, Fujita, Masaki , Greenspan, Susan L., Halbout, Philippe , Hochberg, Marc C. , Jeray, Kyle J. , Kearns, Ann E. , King, Toby, Koinis, Thomas F., Koontz, Jennifer Scott , Kužma, Martin , Lindsey, Carleen, Lorentzon, Mattias , Lyritis, George P., Michaud, Laura Boehnke, Miciano, Armando S., Mujahid, Nadia , Olenginski, Thomas P. , Puzas, J. Edward, Rizou, Stavroula , Thompson, Elizabeth , Tosi, Laura L. , Tracer, Howard, Lorentzon, Mattias , Åkesson, Kristina , Clarke, B.L. , Cooper, Cyrus , Javaid, M K , Morin, Suzanne N , Napoli, Nicola , Rosen, Clifford J. , Saag, Kenneth G. , Khosla, Sundeep , Kiel, Douglas P.

Mayo Clinic

Journal of Orthopaedic Trauma | March 20, 2020 | Volume: 34 | Issue: 4 | Pages: e125-e141

10.1097/bot.0000000000001743 | PMID 32195892 Get It

Abstract Osteoporosis-related fractures are undertreated, due in part to misinformation about recommended approaches to patient care and discrepancies among treatment guidelines. To help bridge this gap and improve patient outcomes, the American Society for Bone and Mineral Research assembled a multistakeholder coalition to develop clinical recommendations for the optimal prevention of secondary fractureamong people aged 65 years and older with a hip or vertebral fracture. The coalition developed 13 recommendations (7 primary and 6 secondary) strongly supported by the empirical literature. The coalition recommends increased communication with patients regarding fracture risk, mortality and morbidity outcomes, and fracture risk reduction. Risk assessment (including fall history) should occur at regular intervals with referral to physical and/or occupational therapy as appropriate. Oral, intravenous, andsubcutaneous pharmacotherapies are efficaciousandcanreduce risk of future fracture.Patientsneededucation,however, about thebenefitsandrisks of both treatment and not receiving treatment. Oral bisphosphonates alendronate and risedronate are first-line options and are generally well tolerated; otherwise, intravenous zoledronic acid and subcutaneous denosumab can be considered. Anabolic agents are expensive butmay be beneficial for selected patients at high risk.Optimal duration of pharmacotherapy is unknown but because the risk for second fractures is highest in the earlypost-fractureperiod,prompt treatment is recommended.Adequate dietary or supplemental vitaminDand calciumintake shouldbe assured. Individuals beingtreatedfor osteoporosis shouldbe reevaluated for fracture risk routinely, includingvia patienteducationabout osteoporosisandfracturesandmonitoringfor adverse treatment effects.Patients shouldbestronglyencouraged to avoid tobacco, consume alcohol inmoderation atmost, and engage in regular exercise and fall prevention strategies. Finally, referral to endocrinologists or other osteoporosis specialists may be warranted for individuals who experience repeated fracture or bone loss and those with complicating comorbidities (eg, hyperparathyroidism, chronic kidney disease).©2019American Society for Bone andMineral Research.
What's in Your CART? Clinical insights on challenges in mononuclear cell collection for CAR‐T therapy
Annen, Kyle , Zubair, Abba C. , Schwartz, E. von, Szczepiorkowski, Zbigniew M. , Zubair, Abba C , Schwartz, Eileen, Schwartz, Joseph E. , Annen, Kyle

Mayo Clinic

Journal of Clinical Apheresis | March 18, 2020 | Volume: 35 | Issue: 3 | Pages: 234-235

10.1002/jca.21776 | PMID 32186782 Get It

Recognizing “diagnostic futility” ‐ stopping earlier to protect patients
Oren, Ohad , Kyle, Robert A. , Steensma, David P.

Mayo Clinic

American Journal of Hematology | March 16, 2020 | Volume: 95 | Issue: 6 | Pages: 580-582

10.1002/ajh.25786 | PMID 32176357 Get It

Clinical and cytogenetic features of nonsecretory multiple myeloma (NSMM) in the era of novel agent induction therapy: The Mayo Clinic experience.
Nandakumar, Bharat , Lacy, Martha Q. , Kapoor, Prashant , Kourelis, Taxiarchis , Warsame, Rahma , Hayman, Suzanne R. , Hwa, Yi L. , Fonder, Amie , Kyle, Robert A. , Kumar, Shaji , Gonsalves, Wilson I. , Buadi, Francis K. , Dispenzieri, Angela , Dingli, David , Lin, Yi , Muchtar, Eli , Go, Ronald S. , Leung, Nelson , Gertz, Morie A. , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 37 | Issue: 15_suppl | Pages: e19519-e19519

10.1200/jco.2019.37.15_suppl.e19519 Get It

e19519 Background: NSMM is a rare subtype of myeloma that has not been well characterized in the era of novel agent induction therapy. Thus, we evaluated the clinical and cytogenetic features of patients with newly diagnosed NSMM evaluated at our institution. Methods: We evaluated all NSMM patients seen at the Mayo Clinic, Rochester from 2008-2017 based on the absence of a detectable monoclonal protein in their serum and urine electrophoresis and having a concurrent involved serum immunoglobulin light chain of less than 5 mg/dL. Survival analysis was performed by the Kaplan-Meier method and clinical and cytogenetic features were reported descriptively. Results: This cohort consisted of 30 consecutive patients with NSMM with a median age of 62 years (40-79) of which 16 (53%) were male. The median bone marrow plasma cell involvement was 70% (Range: 0 – 100). There were 3/25 (12%) patients who presented with a creatinine of 2 mg/dL or greater and 6/23 (26%) patients who presented with hypercalcemia (11 mg/dL or greater). The ISS classification of this cohort is as follows: Stage 1- 8 (36%) patients, Stage 2- 3 (14%) patients and Stage 3- 11 (50%) patients. There were 6 (21%) out of 28 patients with high risk cytogenetics (either del 17p, t(4;14), t(14;16) or t(14;20). The distribution of primary cytogenetic abnormalities among this cohort was as follows: t(11;14) – 16 (57%), t(4;14) – 1 (4%), trisomies – 6 (21%) and other - 5 (13%). The median overall survival (OS) for patients in this cohort was 59 months (95% CI: 34 – 64). In comparison to a control cohort of newly diagnosed secretory myeloma patients matched for age, gender and year of diagnosis in a 1:2 ratio, the median OS was worse for the NSMM cohort but this was not statistically significant (59 vs. 92 months, p = 0.257). Conclusions: Patients diagnosed with NSMM had a predisposition towards having a t(11;14) primary cytogenetic abnormality. In the era of novel agent induction therapy, they may have a survival outcome that may be worse than newly diagnosed secretory myeloma patients.
Prognosis of young patients with monoclonal gammopathy of undetermined significance.
Li, Pang , Kumar, Shaji , Kyle, Robert A. , Lakshman, Arjun , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 37 | Issue: 15_suppl | Pages: 8049-8049

10.1200/jco.2019.37.15_suppl.8049 Get It

8049 Background: Monoclonal gammopathy of undetermined significance (MGUS) is rare in young patients (pts; age <40 years at diagnosis), with a prevalence of < 0.3%, representing approximately 2% of all patients with MGUS. We hypothesized that MGUS detected in pts <40 years of age may be associated with a higher risk of progression. Methods: We identified 249 pts with MGUS <40 yrs old, evaluated at Mayo Clinic, Rochester from 1997 to 2016. The endpoint was time to progression assessed by Kaplan-Meier method. Results: 119 were male, 130 were female. Most (n= 179, 72%) were diagnosed between the ages of 30-39. The type of MGUS was IgG 69%, IgA 10%, IgM 15%, and other 5%. 135 pts (54%) had concurrent immune-related conditions, including autoimmune, inflammatory, and infectious disorders at the time of diagnosis of MGUS. Pts without immune-related conditions tend to have higher M protein compared to pts with immune-related conditions (mean, 0.36 gm/dl VS 0.20 gm/dl, p =0.057). During follow up, the M protein resolved in 36 patients. The M protein was more likely to resolve in pts with immune-related conditions compared with pts without immune-related conditions (RR 1.91, 95% CI 1.02-3.59). Progression was seen in 16 pts: 9 smoldering multiple myeloma (SMM), 4 multiple myeloma (MM), 1 macroglobulinemia, 2 non-Hodgkin’s lymphoma. The rate of progression to SMM, MM, or related disorder at 5 and 10 years was 6.0% and 13.8%, respectively. The size of M protein was a significant risk factor for progression (HR 4.23, 95% CI 2.17-7.91) The risk of progression at 5 and 10 years for pts with immune-related conditions concurrently present when MGUS was first diagnosed was 1.5% and 10.1% respectively; corresponding rate in pts without immune-related conditions at the time of diagnosis was higher at 12.3% and 18.9%, respectively (p =0.016), (HR 2.36, 95% CI 0.85-6.52). Similar results were seen when patients in whom the M protein resolved were excluded. Conclusions: Young patients with MGUS may have a higher risk of progression, 1.4% per year; approximately 50% are diagnosed in the setting of immune-related disorders. When occurring in the setting of immune related disorders, the M protein is smaller, more likely to resolve, and may have a lower risk of progression than in pts in whom MGUS is detected without concurrent immune-related disorder.
Continued improvement in survival in multiple myeloma (MM) including high-risk patients.
Nandakumar, Bharat , Kapoor, Prashant , Lacy, Martha Q. , Hwa, Yi L. , Hayman, Suzanne R. , Kourelis, Taxiarchis , Warsame, Rahma , Hobbs, Miriam, Kyle, Robert A. , Kumar, Shaji , Binder, Moritz , Dispenzieri, Angela , Buadi, Francis K. , Gertz, Morie A. , Dingli, David , Leung, Nelson , Gonsalves, Wilson I. , Muchtar, Eli , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 37 | Issue: 15_suppl | Pages: 8039-8039

10.1200/jco.2019.37.15_suppl.8039 Get It

8039 Background: Treatment of MM has evolved significantly over the past decade, with increasing use of multi-drug combinations for initial therapy. In addition, supportive care approaches have also improved. We examined how these improvements have translated to survival outcomes in patients with newly diagnosed MM. Methods: Patients (n=3449) with a diagnosis of MM made between 2004 and 2017 and seen at Mayo Clinic within six months of the diagnosis, were included in this analysis. Patients were divided into three groups based on the year of diagnosis; group 1- 2004-07 (n=831), group 2-2008-12 (n=1161), and group 3-2013-17 (n=1457). Survival of the groups were estimated using Kaplan-Meier method, and compared using log rank test. Results: The median age was 64 years (22 to 96); 60% were male and 40% were female. 14% were >75 years, 33% were aged 65-75 and 53% were <65 years. The median overall survival for the whole cohort was 5.7 years (95%CI; 5.4, 6.3). The median OS for the groups 1, 2 and 3 were 3.9, 6.3 and NR, respectively; p<0.001. The 4-year survival estimates were 50%, 62%, and 75%, respectively. We then explored the improvements in patient subgroups. While all patients experienced improvements in OS over time, improvement in group 3 was most prominent for those >75 years. In patients <65 years, the 4-yr OS for groups 1, 2 and 3 were 57, 71, and 79% respectively. In patients 65-75 years of age, the 4-yr OS for groups 1, 2 and 3 were 48, 60, and 75% respectively. In patients >75 years, the 4-yr OS for groups 1, 2 and 3 were 24, 35, and 56% respectively. While patients with high-risk disease did not see as much benefit in the earlier period, substantial progress was seen in the last group. The 3-yr OS for patients with high-risk cytogenetics were 52, 55, and 73% for groups 1, 2 and 3 compared to 67, 75, and 85% for standard-risk cytogenetics respectively. 2067 patients were staged according to the International Staging System and the median OS for stages 1, 2 and 3 were 6.5, 4.6 and 2.4 in group 1; 9.2, 6.6 and 3.5 in group 2 and NR for any of the stages in group 3. Conclusions: The results confirm continued improvement in survival of newly diagnosed multiple myeloma patients, including elderly and high-risk MM.
Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity.
Tschautscher, Marcella , Lacy, Martha Q. , Kapoor, Prashant , Hayman, Suzanne R. , Lust, John A., Kourelis, Taxiarchis , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Jevremović, Dragan , Buadi, Francis K. , Gertz, Morie A. , Dispenzieri, Angela , Dingli, David , Leung, Nelson , Go, Ronald S. , Lin, Yi , Gonsalves, Wilson I. , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 37 | Issue: 15_suppl | Pages: 8034-8034

10.1200/jco.2019.37.15_suppl.8034 Get It

8034 Background: Minimal residual disease (MRD) assessment in multiple myeloma (MM) has improved our ability to assess disease activity, resulting in more advanced prognostication. While MRD assessment remains confined to the bone marrow (BM) plasma cell population, serum studies including immunofixation (IFE) are required to complete response evaluation. The significance of those who are MRDneg yet have detectable monoclonal protein through IFE remains unclear. Methods: We retrospectively studied 256 MM patients who had MRD assessment via the Euroflow multiparametric flow cytometry on the BM with concomitant serum IFE testing. Patients who were MRDneg were included in the study. Outcomes included probability of disease progression (PD) at 1 year. The Cox-proportional hazards model was used to compare probability of PD among different groups. Time to progression (TTP) was calculated as the difference from date of MFC analysis to PD in months. Results: Among the entire cohort, 178 (70%) patients were MRDneg and median follow-up from MRD assessment was 6.3 months. Among these patients, 74 (42%) had a positive IFE at the time of MRD analysis. Within the MRDneg/IFEpos group, 31 (42%) patients remained IFEpos after a median follow up of 5.5 mo from initial MRD/IFE testing while 34 patients eventually became IFEneg after a median of 2.8 mo with no subsequent IFE available in 9 patients. The 1 year probability of PD in the MRDneg/IFEneg group was 20% compared to 41% in the MRDneg/IFEpos group (P < 0.01, Wilcoxon test). When comparing subsequent IFE status in those who were MRDneg/IFEpos, those who remained IFEpos had a trend towards shorter TTP compared to patients who later became IFEneg. Conclusions: Persistent monoclonal protein in the face of MRD negativity predicts for a shorter TTP. This likely reflects persistent disease that was not sampled on the BM aspirate in many of these patients compared to those who eventually become IFEneg with a trend towards longer TTP owing to the prolonged half-life and therefore clearance of M protein. This supports the current strategy of assessing for MRD at the time of suspected complete response to reduce the chance of positive MRD tests and thus avoidance of multiple BM exams.